

where (a) indicates bonding to the B group and (b) indicates bonding to respective positions within the heterocycle group;

each R_{19} is independently selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 alkoxy, ester, ether, thioether, aminoalkyl, halogen, alkyl ester, aryl ester, amide, aryl amide, alkyl halide, alkyl amine, alkyl sulfonic acid, alkyl nitro, thioester, sulfonyl ester, halosulfonyl, nitrile, alkyl nitrile, and nitro;

q is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11; and each R_{16} is independently selected from the group consisting of hydrogen, halogen, alkyl, NO_2 -, CN, and substituted alkyl.

50. The compound of claim **49**, wherein R_1 is a polypeptide.

51. The compound of claim **50**, wherein the polypeptide is an antibody.


52. The compound of claim **51**, wherein the antibody is herceptin.

53. The compound of claim **49**, wherein R_2 is a polypeptide.

54. The compound of claim **53**, wherein the polypeptide is an antibody.

55. The compound of claim **54**, wherein the antibody is herceptin.

56. The compound of claim **49**, comprising Formula (XXXI-A):



57. A pharmaceutical composition comprising a compound of any of claims **1-38** and **42-56** and a pharmaceutically acceptable carrier, excipient, or binder.

* * * * *